The nation of Zimbabwe has declined a major American healthcare agreement valued at $367m (£272m) spanning five years due to the United States' insistence on confidential information.
The decision came to light following a official document from December was leaked, revealing that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official representative has since stated that the US was demanding access to health data for scientific study and commercial purposes while was not willing to share the resulting advantages from any future medical innovations.
"We will now turn to the challenging and unfortunate task of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged further negotiations to find a agreement suitable to all parties so the country's critical HIV treatment initiative can proceed.
Wider Implications
This development comes after a comparable case in Kenya, where a court blocked a similar deal with the US after legal challenges were raised about the safety of Kenyans' health data.
After resuming office recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government agreements to boost openness and accountability.
Based on statements, Sixteen nations in Africa have to date signed these new agreements, representing more than $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation could have provided extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy via American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"Our nation was requested to surrender its biological resources and data for a long time, with no corresponding guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that provided information," his statement read.
"Effectively, our country would supply the basic resources for medical research with no assurance that the resulting innovations would be accessible to our citizens if a new disease outbreak emerge."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were undermining structures already set up via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This framework is intended to ensure that when a nation contributes its data, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the capability to create them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage ongoing dialogue with our US partners on how future collaboration could be arranged in a manner that respects the independence and dignity of each country."
Medical Community Reaction
Medical experts expressed it understood the government's concerns, but suggested that negotiations should continue since much of the country's HIV programmes relied on external financing.
"In cases where technical issues exist, including those relating to data governance or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," it added.
The situation underscores the complex tensions between receiving much-needed international aid and protecting a country's data in an ever more data-driven world.